Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders
Phytotherapy Research · 2025
DOI: 10.1002/ptr.70051 ↗At a glance
Übersichtsarbeit in Phytotherapy Research, 2025. Written by Sonali Khanal and 9 co-authors. Institution: School of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan, India. Major MEDLINE topics: TOR Serine-Threonine Kinases, Signal Transduction, Neoplasms, Phytochemicals. Cited 7 times so far (Crossref); 118 references. The full text is freely available (open access, CC BY 4.0). Funded by: Grantová Agentura České Republiky, Project GACR.
Abstract (original language)
Deregulation of the mechanistic target of the rapamycin (mTOR) pathway plays an important role in cancer genesis and progression, making it an attractive target for cancer treatment. Disrupting the mTOR pathway contributes to uncontrolled cell growth, increased proliferation, and enhanced cell survival, all of which are hallmarks of cancer. The findings imply that the deregulation of the mTOR pathway in cancer provides a compelling basis for therapeutic treatments. Phytochemicals such as flavonoids and polyphenols have been shown to play a key role in suppressing different kinases implicated in PI3K/AKT/mTOR signaling cascades. A thorough study of the molecular connections between bioactive substances, mTOR signaling, and autophagy activation can lead to the creation of personalized treatments that work better and have fewer side effects. Finding out how important it is to target the mTOR pathway and how to use bioactive chemicals from plants to treat cancer are both important discoveries that could lead to more precise medicine and the development of effective cancer drugs. Finally, targeting mTOR pathways using plant‐derived chemicals may be a promising therapy strategy for cancer. This review tries to summarize putative plant bioactive chemicals that act on malignancies via mTOR signaling pathways. Furthermore, the paper discusses the role of the mTOR pathway in cancer, specifically its influence on cell growth, proliferation, and survival.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan, India.
- Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.
- Pharmacy Discipline, Khulna University, Khulna, Bangladesh.
- School of Biological and Environmental Science, Shoolini University of Biotechnology and Management Sciences, Solan, India.
- Centre of Advanced Innovation Technologies, VSB - Technical University of Ostrava, Ostrava-Poruba, Czech Republic.
- Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.
ORCID profiles: Rachna Verma, Kamil Kuca, Raihan Chowdhury
Funding
- Grantová Agentura České Republiky
- Project GACR
Cite
APA
Khanal, S., Pillai, M., Bhuia, M. S., Islam, M. T., Sharma, O., Verma, R., Nepovimova, E., Kuca, K., Kumar, D., & Chowdhury, R. (2025). Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders. Phytotherapy Research. https://doi.org/10.1002/ptr.70051
Vancouver
Khanal S, Pillai M, Bhuia MS, Islam MT, Sharma O, Verma R, et al. Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders. Phytotherapy Research. 2025. doi:10.1002/ptr.70051
BibTeX
@article{Khanal2025,
author = {Khanal, Sonali and Pillai, Manjusha and Bhuia, Md Shimul and Islam, Muhammad Torequl and Sharma, Onkar and Verma, Rachna and Nepovimova, Eugenie and Kuca, Kamil and Kumar, Dinesh and Chowdhury, Raihan},
title = {Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.70051}
}
EUVIMED